Omeros (OMER) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.10
- Estimate
- -$0.33
- Surprise
- +128.8%
- Revenue (period 2026-06-30)
- $28.5M
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
Omeros (OMER) beat the -$0.33 estimate with adjusted EPS of $0.10 — a large 128.8% upside surprise.
Coverage in the report window
- 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga, 2026-08-13
- Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday — benzinga, 2026-08-13
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates OMER Sell at 5.2/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +128.8% surprise compares with a +80.1% four-quarter average. Next scheduled report: 2026-11-16.
What argues against it
- Concentration risk — Product: YARTEMLEA
- Concentration risk — Supplier: Lonza
- Risk below floor (1.8 < 2.5)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.78
- Price target
- $23.38
- Stop
- $15.63
- Upside to target
- +39.3%
- Reward-to-risk
- 3.6:1
At 14.3× trailing and 14.2× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-16 — shown for context, not personalized investment advice.
OMER at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.27B
- P/E (fwd)
- 14.2
- P/E (ttm)
- 14.3
- 52-week range
- $6.70–$21.24
- Off 52-week high
- 21.0%
- RSI (14)
- 45
- Volume vs avg
- 0.94×
- Score today
- 5.2/10